Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
Couple this with the fact that today, 5.7M Americans are living with Alzheimer’s disease, and by 2050, this number is projected to rise to nearly 14M. Even amidst such alarming statistics, testing for cognitive issues or neurocognitive disorders is still in the dark ages. Cognivue technology was intuitively designed to eliminate these challenges.![]()
Over the past year, we have invested a significant amount of resources into building out customer channels in optometry, audiology, retail pharmacy, employee wellness, assisted living, rehabilitation, and home health
Share this Article:
Tweet
|
Company
Cognivue
Headquarters
New York
Management
Tom O'Neill, President & CEO
Description
Cognivue is a risk assessment test company that identifies changes in cognitive function that can be indicative of early dementia or Alzheimer's Disease. It objectively, quantitatively and reliably identify changes in cognitive function that can be indicative of early dementia or Alzheimer's Disease. The company allows clinicians the opportunity to establish a baseline cognitive score that can be monitored over time. The company measures and monitors cognitive health by testing four key cognitive domains. This ten-minutes test helps in measuring the tracking movement, vision, perception and memory of letters, words, shapes, and motion. Cognivue is based on psychophysical research and neurophysiology
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info